Reversal of established lupus nephritis and prolonged survival of New Zealand black x New Zealand white mice treated with the topoisomerase I inhibitor irinotecan.
Systemic lupus erythematosus is a chronic autoimmune disorder that predominantly affects women of childbearing age. Lupus-associated glomerulonephritis is a major cause of mortality in these patients. Current treatment protocols for systemic lupus erythematosus include cyclophosphamide, prednisolone, azathioprine, and mycophenolate mofetil. However, in mice none of these agents alone or in combination were shown to reverse established proteinuria. Using New Zealand Black x New Zealand White F1 mice, we report that administration of the topoisomerase I inhibitor irinotecan from week 13 completely prevented the onset of proteinuria and prolonged survival up to at least 90 wk without detectable side effects. Furthermore, application of irinotecan to mice with established lupus nephritis, as indicated by grade 3+ (> or =300 mg/dl) and grade 4+ (> or =2000 mg/dl) proteinuria and, according to a median age of 35 wk, resulted in remission rates of 75% and 55%, respectively. Survival was significantly prolonged with 73 wk (grade 3+ and 4+ combined) versus 40 wk for control animals. Although total IgG and anti-dsDNA Abs in the serum and mesangial IgG deposits in the kidneys were not reduced in irinotecan-treated mice, subendothelial immune deposits were considerably diminished, suggesting a prevention of glomerular basement membrane disruption. This effect was accompanied by increased rates of ssDNA breaks and inhibition of renal cell apoptosis being different to what is known about irinotecan in anticancer therapy. In conclusion, our data provide evidence that irinotecan might represent an entirely new strategy for the treatment of systemic lupus erythematosus.
Frese-Schaper
Manuela
M
Department of Clinical Research, University Hospital Bern, Bern, Switzerland.
Zbaeren
Jakob
J
Gugger
Mathias
M
Monestier
Marc
M
Frese
Steffen
S
D000818:Animals; D001327:Autoimmune Diseases / Q000201:enzymology / Q000401:mortality / Q000517:prevention & control; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003433:Crosses, Genetic; D004264:DNA Topoisomerases, Type I / Q000502:physiology; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D000077146:Irinotecan; D008181:Lupus Nephritis / Q000201:enzymology / Q000276:immunology / Q000401:mortality* / Q000517:prevention & control*; D051379:Mice; D008814:Mice, Inbred NZB; D011507:Proteinuria / Q000201:enzymology / Q000276:immunology / Q000401:mortality / Q000517:prevention & control; D011897:Random Allocation; D016019:Survival Analysis; D013997:Time Factors; D059004:Topoisomerase I Inhibitors
D004791:Enzyme Inhibitors; D059004:Topoisomerase I Inhibitors; D000077146:Irinotecan; D004264:DNA Topoisomerases, Type I; D002166:Camptothecin